Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-T and anti-PD1 in Advanced Solid Tumors
NCT05798533Phase 1Unknown
- Sponsor
- BGI
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Neo-T in solid tumor, sponsored by BGI. Primary endpoint: Adverse Events at 1 month. Status: unknown.
02
Drugs
Neo-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05798533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798533.